Lymph node dissection for stage III melanoma

Maggie L. Diller, Benjamin M. Martin, Keith A. Delman

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Locoregional spread of melanoma to its draining lymph node basin is the strongest negative prognostic factor for patients. Exclusive of clinical trials, patients with sentinel lymph node-positive (microscopic) or clinically palpable (macroscopic) nodal disease should undergo lymphadenectomy. This article reviews the management and technical aspects of surgical care for regional metastases. Adjunct therapies (immunotherapy, targeted therapy, and radiation) may supplement lymphadenectomy in certain patient populations. Surgical morbidity after lymphadenectomy can be substantial, creating opportunities for improvement via minimally invasive techniques or refined patient selection.

Original languageEnglish (US)
Pages (from-to)261-277
Number of pages17
JournalSurgical Oncology Clinics of North America
Issue number2
StatePublished - Apr 1 2015


  • Locoregional spread
  • Lymphadenectomy
  • Stage III melanoma
  • Videoscopic inguinal lymphadenectomy


Dive into the research topics of 'Lymph node dissection for stage III melanoma'. Together they form a unique fingerprint.

Cite this